CymaBay Therapeutics, Inc.
CBAY · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Market Cap | $2,676,698 | $1,576,255 | $1,118,547 | $854,308 |
| - Cash | $206,535 | $273,721 | $35,482 | $59,150 |
| + Debt | $114,494 | $104,297 | $99,622 | $95,167 |
| Enterprise Value | $2,584,657 | $1,406,831 | $1,182,687 | $890,325 |
| Revenue | $57 | $0 | $31,016 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | $1 | -$215 | $30,805 | -$199 |
| % Margin | 1.8% | – | 99.3% | – |
| EBITDA | -$36,765 | -$38,510 | $4,021 | -$24,176 |
| % Margin | -64,500% | – | 13% | – |
| Net Income | -$41,902 | -$33,882 | -$808 | -$35,084 |
| % Margin | -73,512.3% | – | -2.6% | – |
| EPS Diluted | -0.37 | -0.32 | -0.008 | -0.36 |
| % Growth | -15.6% | -3,950.6% | 97.8% | – |
| Operating Cash Flow | -$27,380 | -$26,145 | -$25,437 | $6,431 |
| Capital Expenditures | -$180 | $0 | -$70 | -$195 |
| Free Cash Flow | -$27,560 | -$26,145 | -$25,507 | $6,236 |